Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Blood (2022) 140 (Supplement 1): 4426–4427.

https://doi.org/10.1182/blood-2022-164572

Published: 2022

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi

Blood (2022) 140 (Supplement 1): 10131–10132.

https://doi.org/10.1182/blood-2022-164722

Published: 2022

Journal Articles

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Yael C Cohen, Mor Zada, Shuang-Yin Wang, Ohad S. Bentur, Evgeni Chubar, Amos Cohen, Noa Lavi, Hila Magen, Moshe Gatt, Miri Zektser, Merav Leiba, Galia Stemer, Tamir Shragai, Irit Avivi, Assaf Weiner, Ido Amit

Blood (2021) 138 (Supplement 1): 2725.

https://doi.org/10.1182/blood-2021-149701

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Yael C Cohen, Hila Magen, MD, Noa Lavi, MD, Moshe E. Gatt, MD, Evgeni Chubar, MD, Natalia Kreiniz, Tamar Tadmor, MD, Svetlana Trestman, MD, Roy Vitkon, MD, Ory Rouvio, Olga Shvetz, MD, Adir Shaulov, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2018-99-114217

Published: 2018

Journal Articles

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

Adi Shacham Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, MD, Ilana Hellman, Liat Shargian, Anna Gourevietch, Evgeni Chubar, MD, Roy Ratzon, MD, Uri Rozovski

Blood (2017) 130 (Supplement 1): 5249.

https://doi.org/10.1182/blood.V130.Suppl_1.5249.5249

Published: 2017

Journal Articles

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Adi Shacham Abulafia, MD, Pia Raanani, MD, David Lavie, MD, Yulia Volchek, MD, Ron Ram, MD, Ilana Hellmann, MD, Liat Shargian, MD, Anna Gourevietch, MD, Evgeni Chubar, MD, Roy Ratzon, BSC, Uri Rozovski, MD

Blood (2015) 126 (23): 5155.

https://doi.org/10.1182/blood.V126.23.5155.5155

Published: 2015

Journal Articles

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Noa Lavi, MD, Maya Koren-Michowitz, MD, Avi Leader, MD, Adi Shacham-Abulafia, MD, Shirley Shapira, MD, Najib Dally, MD, Evgeni Chubar, MD, Elena Mishchenko, MD, Martin H. Ellis, MD

Blood (2015) 126 (23): 4081.

https://doi.org/10.1182/blood.V126.23.4081.4081

Published: 2015

Journal Articles

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Eli Muchtar, MD, Moshe Gatt, MD, Ory Rouvio, Chezi Ganzel, Evgeni Chubar, MD, Celia Suriu, MD, Tamar Tadmor, Olga Shevetz, MD, Noa Lavi, MD, Tzippy Shochat, MSc, Yael C Cohen, MD, Irit Avivi, MD, Pia Raanani, MD, Hila Magen, MD

Blood (2015) 126 (23): 5371.

https://doi.org/10.1182/blood.V126.23.5371.5371

Published: 2015

Journal Articles

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Martin H. Ellis, MD, Noa Lavi, MD, Elena Mishchenko, MD, Najib Dally, MD, David Lavie, MD, Anna Courevitch, MD, Odit Gutwein, MD, Shlomo Bulvik, MD, Andrei Braester, MD, Evgeni Chubar, MD, Sigal Tavor, MD, Adrian Duek, MD, Ilya Kirgner, MD, Maya Koren-Michowitz, MD

Blood (2014) 124 (21): 1830.

https://doi.org/10.1182/blood.V124.21.1830.1830

Published: 2014

NARROW

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only